Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 Infection (COVID-19)

Summary

The coronavirus disease of 2019 (COVID-19) has affected over 2.4 million individuals worldwide and has resulted in \>171,000 deaths. Cardiovascular disease (CVD) is an important contributor to death in these patients. Those who develop cardiac injury during infection have a 4-fold increased risk of death. Furthermore, pre-existing CVD or cardiovascular risk factors (e.g. diabetes, hypertension) are associated with worse outcomes. Given the recent emergence of this disease, there is limited understanding of:

(i) the risk factors for cardiovascular events, (ii) blood biomarkers for early recognition, and drug targeting, of patients at risk of adverse outcomes, and (iii) the short term subclinical and clinical cardiovascular manifestations in those who survive to discharge.

Conditions

• COVID-19 Respiratory Infection

Interventions

DIAGNOSTIC_TEST

Bloodwork, Echocardiogram, PET/MRI

The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.

DIAGNOSTIC_TEST

Bloodwork, Echocardiogram, MRI

The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.

Sponsors & Collaborators

• University Health Network, Toronto

  lead OTHER

Principal Investigators

• Dinesh Thavendiranathan · University Health Network, Toronto

• Kate Hanneman · University Health Network, Toronto

• Kathryn Howe · University Health Network, Toronto

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-07-01

Primary Completion

2022-04-01

Completion

2023-09-30

Countries

• Canada

Study Locations